New Model for Follicular Lymphoma Treatment
Author Information
Author(s): Cèlia Dobaño-López, Juan García Valero, Ferran Araujo-Ayala, Ferran Nadeu, Fabien Gava, Carla Faria, Marine Norlund, Renaud Morin, Pascale Bernes-Lasserre, Fabian Arenas, Marta Grau, Cristina López, Irene López-Oreja, Neus Serrat, Ares Martínez-Farran, Lluís Hernández, Heribert Playa-Albinyana, Rubén Giménez, Silvia Beà, Armando López-Guillermo, Laura Magnano, Dolors Colomer, Christine Bezombes, Patricia Pérez-Galán
Primary Institution: Fundació de Recerca Clínic Barcelona - Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
Hypothesis
Can patient-derived lymphoma spheroids effectively mimic the immune environment and signaling pathways of follicular lymphoma for therapeutic testing?
Conclusion
The study demonstrates that patient-derived lymphoma spheroids maintain key immune interactions and can be used to identify new therapeutic targets like galectin-9.
Supporting Evidence
- The FL-PDLS model recapitulates the immune tumor microenvironment and signaling pathways of follicular lymphoma.
- Blocking galectin-9 improves the efficacy of rituximab in the treatment of follicular lymphoma.
- The study provides a new platform for personalized medicine in treating follicular lymphoma.
Takeaway
Researchers created a new model using cells from patients with follicular lymphoma to better understand the disease and test treatments.
Methodology
The study involved generating patient-derived lymphoma spheroids from follicular lymphoma samples and analyzing their immune profiles and responses to treatments.
Limitations
The model may not fully replicate all aspects of the tumor microenvironment found in vivo.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website